PGI Chandigarh has been chosen as one of the national centers by the Indian Council of Medical Research (ICMR) to conduct the trial of convalescent plasma therapy in patients with serious COVID infection. The approval was received last Friday.
With this approval, serious sick COVID 19 positive patients admitted in Nehru Hospital Extension Block will be eligible to get this form of treatment. In this trial, antibodies from the blood of patients who have recovered from COVID-19 are used to treat severely infected patients. However, the exact role of this therapy in the treatment of COVID positive patients is still debatable and hence ICMR decided to conduct a multicentric study to clarify its role in these patients.
The collaborative departments for this trial are Depts of Internal Medicine, Anaesthesia and Intensive Care, Transfusion Medicine, Endocrinology, Virology, and community Medicine. The team of doctors from the Dept of Transfusion Medicine will start getting in touch with patients who have recovered from COVID 19 infection and would explain the nature of the study.
The study is aimed at assessing the safety and efficacy of convalescent plasma to limit complications in Covid-19 patients.